Boston Scientific Corp (BSX)
NYSE · Healthcare · Medical Devices
Boston Scientific Corp is a Healthcare company with a market capitalization of $73.25B and a trailing P/E ratio of 20.5.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 22, 2026 | $0.80 | $0.79 | +1.3% |
| Q4 2025 | February 4, 2026 | $0.80 | $0.78 | +2.6% |
| Q3 2025 | October 22, 2025 | $0.75 | $0.71 | +5.6% |
| Q2 2025 | July 23, 2025 | $0.75 | $0.73 | +2.7% |
| Q1 2025 | April 23, 2025 | $0.75 | $0.67 | +11.9% |
| Q4 2024 | February 5, 2025 | $0.70 | $0.66 | +6.1% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 28,281,040 | 1.89% | 1.7 | +1.2% |
| June 30, 2026 | 27,938,624 | 1.87% | 1.2 | -6.1% |
| June 15, 2026 | 29,750,309 | 1.99% | 1.4 | -48.3% |
| May 29, 2026 | 57,491,117 | 3.85% | 2.3 | +83.0% |
| May 15, 2026 | 31,423,298 | 2.10% | 1.8 | +9.7% |
| April 30, 2026 | 28,642,737 | 1.92% | 1.4 | +11.8% |
| April 15, 2026 | 25,614,558 | 1.71% | 1.8 | +8.9% |
| March 31, 2026 | 23,529,218 | 1.57% | 1.4 | -7.5% |
Other Medical Devices Stocks
Frequently Asked Questions
What is Boston Scientific Corp's market cap?
As of August 13, 2026, Boston Scientific Corp (BSX) has a market capitalization of $73.25B.
What is Boston Scientific Corp's P/E ratio?
Boston Scientific Corp trades at a trailing price-to-earnings (P/E) ratio of 20.5. Its forward P/E is 15.4.
Does Boston Scientific Corp pay a dividend?
Boston Scientific Corp does not currently pay a dividend.
What sector is BSX in?
Boston Scientific Corp is in the Healthcare sector, specifically the Medical Devices industry.
What is Boston Scientific Corp's short interest?
As of the July 15, 2026 FINRA settlement, 28,281,040 BSX shares were sold short, or 1.89% of shares outstanding. Days to cover: 1.7. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Boston Scientific Corp's revenue?
In its latest reported fiscal year (ending December 31, 2025), Boston Scientific Corp reported revenue of $20.07B and net income of $2.89B.
Ask your own questions about BSX
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.